Schedule II controlled substances
The controlled substances listed in this Code section are included in Schedule II: (1) Any of the following substances, or salts thereof, except those narcotic drugs specifically exempted or listed in other schedules, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis: (A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding naloxone hydrochloride, but including the following: (i) Raw opium; (ii) Opium extracts; (iii) Opium fluid extracts; (iv) Powdered opium; (v) Granulated opium; (vi) Tincture of opium; (vii) Codeine; (viii) Ethylmorphine; (ix) Hydrocodone; (x) Hydromorphone; (xi) Metopon; (xii) Morphine; (xiii) Oripavine; (xiv) Oxycodone; (xv) Oxymorphone; (xvi) Thebaine; (B) Any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identi- cal with any of the substances referred to in subparagraph (A) of this paragraph, except that these substanc- es shall not include the isoquinoline alkaloids of opium; (C) Opium poppy and poppy straw; (D) Cocaine, coca leaves, any salt, compound, derivative, stereoisomers of cocaine, or preparation of coca leaves, and any salt, compound, derivative, stereoisomers of cocaine, or preparation thereof which is chemi- cally equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions which do not contain cocaine or ecgonine; (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation: (A) Alfentanil; (A.1) Alphaprodine; (B) Anileridine; (C) Bezitramide; (C.5) Carfentanil; (D) Dihydrocodeine; (E) Diphenoxylate; (F) Fentanyl; (G) Isomethadone; (G.5) Levo-alphacetylmethadol (some other names: levomethadyl acetate, LAAM); (H) Levomethorphan; (I) Levorphanol; (J) Methazocine; (K) Methadone; (L) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-di-phenyl butane; (M) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenyl-propane-carboxylic acid; (M.3) Norfentanyl; (M.5) Oliceridine; (N) Pethidine (meperidine); (O) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpi-peridine; (P) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate; (Q) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid; (R) Phenazocine; (S) Piminodine; (T) Racemethorphan; (U) Racemorphan; (U.1) Remifentanil; (V) Sufentanil; (V .1) Tapentadol; (V .2) Thiafentanil; (W) 4-anilino-N-phenethyl-4-piperidine (ANPP); (3) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances included as having a stimulant effect on the central nervous system: (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers; (B) Any substance which contains any quantity of methamphetamine, including its salts, isomers, and salts of isomers; (C) Phenmetrazine and its salts; (D) Methylphenidate, including its salts, isomers, and salts of isomers; (E) Reserved; (F) Nabilone; (G) Lisdexamfetamine; (4) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any of the following substances included as having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) Amobarbital; (A.5) Glutethimide; (B) Secobarbital; (C) Pentobarbital; (5) Dronabinol in oral solution labeled in compliance with U.S. Food and Drug Administration requirements.
Drugs - Schedule III
Schedule III controlled substancesSchedule III controlled substances Amended
Amended 2024 The controlled substances listed in this Code section are included in Schedule III: (1) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, included as having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) Those compounds, mixtures, or preparations in dosage unit forms containing any stimulant substances which are listed as excepted compounds by the State Board of Pharmacy pursuant to this article, and any other drug of quantitative composition so excepted or which is the same except that it contains a lesser quantity of controlled substances; (B) Benzphetamine; (C) Chlorphentermine; (D) Clortermine; (E) Phendimetrazine; (2) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances included as having a depressant effect on the central nervous system: (A) Any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or any salts thereof and one or more active medicinal ingredients which are not listed in any schedule; (B) Any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or any salt of any of these drugs and approved by the State Board of Pharmacy for marketing only as a suppository; (C) Any substance which contains any quantity of a derivative of barbituric acid or any salt thereof; (D) Chlorhexadol; (E) Reserved; (F) Lysergic acid; (G) Lysergic acid amide; (H) Methyprylon; (I) Sulfondiethylmethane; (J) Sulfonethylmethane; (K) Sulfonmethane; (L) Tiletamine/Zolazepam (Telazol); (3) Nalorphine; (4) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of the following narcotic drugs, or any salts thereof: (A) Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milli- grams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium; (B) Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milli- grams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; (C) and (D) Reserved; (E) Not more than 1.8 grams of dihydrocodeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; (F) Not more than 300 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milli- grams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; (H) Not more than 50 milligrams of morphine, or any of its salts, per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; (5) The State Board of Pharmacy may except by rule any compound, mixture, or preparation containing any stimulant or depressant substance listed in paragraphs (1) and (2) of this Code section from the application of all or any part of this article if the compound, mixture, or preparation contains one or more active, medici- nal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admix- tures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system; (6) Any anabolic steroid or any salt, ester, or isomer of a drug or substance described or listed in this para- graph, if that salt, ester, or isomer promotes muscle growth. Such term does not include an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the secretary of health and human services for such administration: (A.01) Androstanedione; (A.05) Androstenediol; (A.075) Androstenedione; (A.08) Bolandiol; (A.085) Bolandione; (A.1) Boldenone; (A.5) Boldione (Androsta-1,4-diene-3,17-dione); (A.75) Bromoandrostanedione; (A.85) Chloromethylandrostenediol; (B) Chlorotestosterone; (C) Clostebol; (D) Dehydrochloromethyltestosterone; (D.1) Desoxymethyltestosterone (17a-methyl-5a-androst-2-en-17-ol, madol); (E) Dihydrotestosterone; (F) Drostanolone; (G) Ethylestrenol; (H) Fluoxymesterone; (I) Formebolone; (I.25) Furazabol; (I.3) Furuza; (I.5) Halodrol; (I.75) Hemapolin; (I.8) Mestanolone; (I.85) Mestanolone oxime; (J) Mesterolone; (K) Methandienone; (L) Methandranone; (M) Methandriol; (N) Methandrostenolone; (N.5) Methasterone; (O) Methenolone; (O.25) Methylandrostanol; (O.5) Methylclostebol; (O.7) Methyldienolone; (O.75) Methylhydroxynandrolone; (P) Methyltestosterone; (P .5) Methyltrienolone; (Q) Mibolerone; (R) Nandrolone; (R.5) Norbolethone; (R.75) Norclostebol; (S) Norethandrolone; (S.5) Oxabolone; (T) Oxandrolone; (T.5) Oxyguno; (U) Oxymesterone; (V) Oxymetholone; (V .5) Prostanozol; (W) Stanolone; (X) Stanozolol; (Y) Testolactone; (Z) Testosterone; (Z.5) Tetrahydrogestrinone; (AA) Trenbolone; (AA.5) Trendione; (BB) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione); (CC) 5alpha-androstan-3,6,17-trione; (DD) 6-bromo-androsta-1,4-diene-3,17-dione; (EE) Delta1-dihydrotestosterone; (FF) 3beta,17beta-dihydroxy-5alpha-androstane; (GG) 2alpha,17alpha-dimethyl-17beta-hydroxy-5beta-androstan-3-one; (HH) 13beta-ethyl-17beta-hydroxygon-4-en-3-one; (II) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one; (JJ) 4-hydroxy-androst-4-ene-3,17-dione; (KK) 17beta-hydroxy-androstano[2,3-d]isoxazole; (LL) 4,17beta-dihydroxy-androst-4-en-3-one (4-hydroxytestosterone); (MM) 17alpha-methyl-androsta-1,4-diene-3,17beta-diol; (NN) 6alpha-methyl-androst-4-ene-3,17-dione; (OO) 17alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane; (PP) [3,2-c]pyrazole-androst-4-en-17beta-ol; (7) Ketamine; (8) Dronabinol (synthetic) in sesame oil and encapsulated in a U.S. Food and Drug Administration approved drug product also known as Marinol; (9) Sodium oxybate, when the FDA approved form of this drug is in a container labeled in compliance with subsection (a) or (b) of Code Section 26-3-8, in the possession of a registrant permitted to dispense the drug, or in the possession of a person to whom it has been lawfully prescribed; (10) Buprenorphine; (11) Embutramide; (12) Any drug product in hard or soft gelatin capsule form containing natural dronabinol (derived from the cannabis plant) or synthetic dronabinol (produced from synthetic materials) in sesame oil, for which an abbreviated new drug application (ANDA) has been approved by the FDA under section 505(j) of the Fed- eral Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)) which references as its listed drug the drug product referred to in paragraph (8) of this Code section; (13) Perampanel and its salts, isomers, and salts of isomers.